Answers are grounded in this paper and cite their sources.
Exploratory study evaluates metastatic tumour burden impact on survival in nivolumab-treated mRCC, suggesting new prognostic insights.
Introduction: Prognostic assessment remains fundamental in metastatic renal cell carcinoma (mRCC). Established prognostic models, such as the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and Meet-URO classifications, are widely used but do not directly quantify the metastatic tumour burden. We evaluated the prognostic value of metastatic tumour burden in nivolumab-treated mRCC and developed an exploratory composite prognostic score integrating the tumour burden with systemic inflammation and performance status. Patients and Methods: We retrospectively analysed consecutive patients with mRCC initiating nivolumab as a second- or third-line therapy at a single UK centre between March 2017 and November 2024. Their baseline clinical, laboratory and radiological data were collected. The metastatic tumour burden was defined as involvement of ≥2 metastatic organ sites, excluding lymph nodal, soft tissue, renal, pancreatic and thyroid metastases, while including bone metastases. The Bath score combined the metastatic tumour burden, systemic immune-inflammation index (SII) and Karnofsky performance status (KPS). Overall survival (OS) was analysed using Kaplan–Meier methods and a Cox regression, and the prognostic performance was compared using Harrell’s concordance index (C-index). Results: Fifty-one patients were included. After a median follow-up of 46.1 months, the median OS was 30.4 months. In the univariate analyses, a KPS < 80%, high SII, elevated platelet count and ≥2 metastatic organ sites were significantly associated with inferior OS. A KPS < 80% was the only variable retaining statistical significance in the multivariate analysis. The Bath score was significantly associated with OS (log-rank p < 0.001) and showed a numerically higher C-index than the IMDC and Meet-URO in this cohort (0.779 [optimism corrected, 0.760] vs. 0.641 and 0.706, respectively), with separation of risk groups. Conclusions: In this real-world cohort of nivolumab-treated mRCC, the metastatic tumour burden, systemic inflammation, and performance status were associated with survival. The Bath score should be regarded as exploratory and hypothesis-generating and requires validation in larger contemporary cohorts.
No takes yet. Share an insight, caveat, or question.
Uccello et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: